Shanghai, China – Three products of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") - Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), Firebird2™ Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2™"), and Mustang® Coronary Stent System ("Mustang®"), were selected in the List of the Third Batch of Excellent Domestically Made Medical Products ("the List") released by China Association of Medical Equipment ("CAME") under the commission of the National Health and Family Planning Commission ("NHFPC"), falling into the cardiovascular stent category.
Since November 2016, the CAME started to screen medical products for the List according to three indicators - technical parameter, company's situation, and clinical application assessment. The indicators were independently assessed and the product needs to achieve over 80% of the full mark for each indicator to be selected in the List. It was the first time that the high-value consumables such as cardiovascular stents were included in the selection. Several cardiovascular stent developers signed up for the screening test, but only 10 products were finally listed, and as many as three of them are MicroPort® products, fully demonstrating the competitiveness of its cardiovascular stents.
In particular, the clinical performance of Firehawk® was highly recognized by the assessment panel as it gained a full mark in the clinical application assessment, making it the only product with a full mark in the 10 selected cardiovascular stents as well as the total 155 selected products of 20 categories in the List, which was also rare to see during the first two selections. Firehawk® is MicroPort®'s third generation drug-eluting stent ("DES") used for the treatment of coronary artery stenosis and occlusion following Firebird2® Rapamycin-Eluting Coronary CoCr Stent. It is the world's first and only target eluting stent ("TES"), adopting TARGET Eluting Technique to achieve free redundancy. Its automatic and ultra-micro 3D printing technology enables groove filling, which means that the absorbable drug coating is filled in the groove while the other area of the stent has metal surface. Such unique technology makes Firehawk® combine the merits of bare metal stents and DES. Since it received CFDA approval in 2014, Firehawk® has entered in nearly 400 hospitals of 27 provinces/cities in China, and has gained high market recognition.
The CAME selected the domestically made medical products of good quality, market competitiveness, and development potential to form the List according to the principle of transparency, objectivity and impartiality, aiming to provide references for decision makers of China's healthcare institutions. Such selection activities that attracted wide attention from the industry and the society injected new vitality into the medical device industry and promoted the application of domestically made medical products. As a market leader in the industry of medical device and high-value consumables, MicroPort® will continue to innovate and offer high-quality products to provide patients with more safe, effective, and affordable high-end medical solutions, in response to relative government policies.